Targeted Therapy for Hepatocellular Carcinoma: Co-Delivery of Sorafenib and Curcumin Using Lactosylated pH-Responsive Nanoparticles

被引：43
作者：
Bian, Yun [1 ]
Guo, Dong [2 ]
机构：
[1] Jiangnan Univ, Peoples Hosp Wuxi City 4, Dept Pharm, Affiliated Hosp, Wuxi 214000, Jiangsu, Peoples R China
[2] Jiangnan Univ, Peoples Hosp Wuxi City 4, Affiliated Hosp, 200 Hui He Rd, Wuxi 214000, Jiangsu, Peoples R China
来源：
DRUG DESIGN DEVELOPMENT AND THERAPY | 2020年 / 14卷
关键词：
hepatocellular carcinoma; nanoparticles; pH-responsive; sorafenib; curcumin; SYNERGISTIC ANTITUMOR-ACTIVITY; POLYMER HYBRID NANOPARTICLES; SOLID LIPID NANOPARTICLES; BY-LAYER NANOPARTICLES; IN-VITRO; COMBINATION THERAPY; HYALURONIC-ACID; CANCER THERAPY; DOXORUBICIN; DRUG;
D O I：
10.2147/DDDT.S238955
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Purpose: Hepatocellular carcinoma (HCC) is a leading cancer worldwide. In the present investigation, sorafenib (SFN) and curcumin (CCM) were co-delivered using pH-sensitive lactosylated nanoparticles (LAC-NPs) for targeted HCC treatment. Methods: pH-responsive lactosylated materials were synthesized. SFN and CCM codelivered, pH-responsive lactosylated nanoparticles (LAC-SFN/CCM-NPs) were self-assembled by using the nanoprecipitation technique. The nanoparticles were characterized in terms of particle size, charge and drug release profile. The anti-cancer effects of the nanoparticles were evaluated in human hepatic carcinoma cells (HepG2) cells and HCC tumor xenograft models. Results: LAC-SFN/CCM-NPs are spherical particles with light coats on the surface. The size and zeta potential of LAC-SFN/CCM-NPs were 115.5 +/- 3.6 nm and -34.6 +/- 2.4, respectively. The drug release of LAC-SFN/CCM-NPs in pH 5.5 was more efficient than in pH 7.4. LAC-SFN/CCM-NPs group exhibited the smallest tumor volume (239 +/- 14 mm(3)), and the inhibition rate of LAC-SFN/CCM-NPs was 77.4%. Conclusion: In summary, LAC-SFN/CCM-NPs was proved to be a promising system for targeted HCC therapy.
引用
收藏
页码：647 / 659
页数：13
相关论文
共 62 条
[1]  
[Anonymous], 2019, SEMIN CANC BIOL
[2]   Dual Drug Delivery of Sorafenib and Doxorubicin from PLGA and PEG-PLGA Polymeric Nanoparticles [J].
Babos, Gyorgy ;
Biro, Emese ;
Meiczinger, Monika ;
Feczko, Tivadar .
POLYMERS, 2018, 10 (08)
[3]   Nucleoside-Lipid-Based Nanocarriers for Sorafenib Delivery [J].
Benizri, Sebastien ;
Ferey, Ludivine ;
Alies, Bruno ;
Mebarek, Naila ;
Vacher, Gaelle ;
Appavoo, Ananda ;
Staedel, Cathy ;
Gaudin, Karen ;
Barthelemy, Philippe .
NANOSCALE RESEARCH LETTERS, 2018, 13
[4]   Telodendrimer nanocarrier for co-delivery of paclitaxel and cisplatin: A synergistic combination nanotherapy for ovarian cancer treatment [J].
Cai, Liqiong ;
Xu, Gaofei ;
Shi, Changying ;
Guo, Dandan ;
Wang, Xu ;
Luo, Juntao .
BIOMATERIALS, 2015, 37 :456-468
[5]   Lung cancer combination therapy: doxorubicin and β-elemene co-loaded, pH-sensitive nanostructured lipid carriers [J].
Cao, Chengsong ;
Wang, Qun ;
Liu, Yong .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 :1087-1098
[6]   Codelivery of Sorafenib and Curcumin by Directed Self-Assembled Nanoparticles Enhances Therapeutic Effect on Hepatocellular Carcinoma [J].
Cao, Haiqiang ;
Wang, Yixin ;
He, Xinyu ;
Zhang, Zhiwen ;
Yin, Qi ;
Chen, Yi ;
Yu, Haijun ;
Huang, Yongzhuo ;
Chen, Lingli ;
Xu, Minghua ;
Gu, Wangwen ;
Li, Yaping .
MOLECULAR PHARMACEUTICS, 2015, 12 (03) :922-931
[7]   In Vivo Evaluation of Novel pH-sensitive mPEG-Hz-Chol Conjugate in Liposomes: Pharmacokinetics, Tissue Distribution, Efficacy Assessment [J].
Chen, Daquan ;
Jiang, Xiaoqun ;
Liu, Jia ;
Jin, Xiang ;
Zhang, Can ;
Ping, Qineng .
ARTIFICIAL CELLS BLOOD SUBSTITUTES AND BIOTECHNOLOGY, 2010, 38 (03) :136-142
[8]   The evolving landscape of therapeutic drug development for hepatocellular carcinoma [J].
Chong, Dawn Qingqing ;
Tan, Iain Beehuat ;
Choo, Su-Pin ;
Toh, Han Chong .
CONTEMPORARY CLINICAL TRIALS, 2013, 36 (02) :605-615
[9]   Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method [J].
Chou, Ting-Chao .
CANCER RESEARCH, 2010, 70 (02) :440-446
[10]   Co-delivery of doxorubicin and pH-sensitive curcumin prodrug by transferrin-targeted nanoparticles for breast cancer treatment [J].
Cui, Tongxing ;
Zhang, Sihao ;
Sun, Hong .
ONCOLOGY REPORTS, 2017, 37 (02) :1253-1260
1234567